Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies

Molecular Oncology

Volumn 3, Issue 3, 2009, Pages 238-247

  Rockberg, Johan ^a   Schwenk, Jochen M ^a   Uhlén, Mathias ^a  

^a ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Antibody; Epitope mapping; Growth inhibition; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; PERTUZUMAB; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; EPITOPE MAPPING; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING;

BACTERIA (MICROORGANISMS);

ANIMALS; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CELL LINE, TUMOR; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 67349155587     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.01.003     Document Type: Article

References (28)

1. Agaton C., Falk R., Hoiden Guthenberg I., Gostring L., Uhlen M., and Hober S. Selective enrichment of monospecific polyclonal antibodies for antibody-based proteomics efforts. J. Chromatogr. A 1043 (2004) 33-40
2. Agus D.B., Akita R.W., Fox W.D., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002) 127-137
3. Ben-Kasus T., Schechter B., Sela M., and Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol 1 (2007) 42-54
4. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289
5. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney Jr. D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
6. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., and Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5 (2004) 317-328
7. Gelmon, K., Fumoleau, P., Verma, S., Wardley, A., Conte, P.F., Miles, D., Gianni, L., McNally, V.A., Ross, G.A., Baselga, J., 2008. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Proceedings from ASCO 2008, Abs TBC.
8. Ihaka R., and Gentleman R. R: a language for data analysis and graphics. J. Computat. Graphical Statist. 5 (1996) 299-314
9. Larsson K., Wester K., Nilsson P., Uhlen M., Hober S., and Wernerus H. Multiplexed PrEST immunization for high-throughput affinity proteomics. J. Immunol. Methods 315 (2006) 110-120
10. Lindskog M., Rockberg J., Uhlen M., and Sterky F. Selection of protein epitopes for antibody production. Biotechniques 38 (2005) 723-727
11. Logtenberg T. Antibody cocktails: next-generation biopharmaceuticals with improved potency. Trends Biotechnol 25 (2007) 390-394
12. Menard S., Tagliabue E., Campiglio M., and Pupa S.M. Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol 182 (2000) 150-162
13. Nahta R., Hung M.C., and Esteva F.J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64 (2004) 2343-2346
14. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., and Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol 3 (2006) 269-280
15. Nilsson P., Paavilainen L., Larsson K., Odling J., Sundberg M., Andersson A.C., Kampf C., Persson A., Al-Khalili Szigyarto C., Ottosson J., et al. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 5 (2005) 4327-4337
16. Pal S.K., and Pegram M. Targeting HER2 epitopes. Semin. Oncol 33 (2006) 386-391
17. Pal S.K., and Pegram M. HER2 targeted therapy in breast cancer ... beyond Herceptin. Rev. Endocr. Metab. Disord 8 (2007) 269-277
18. Persson M., Gedda L., Lundqvist H., Tolmachev V., Nordgren H., Malmstrom P.U., and Carlsson J. [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res. 67 (2007) 326-331
19. Popat S., and Smith I.E. Therapy Insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat. Clin. Pract. Oncol 5 (2008) 324-335
20. Portera C.C., Walshe J.M., Rosing D.R., Denduluri N., Berman A.W., Vatas U., Velarde M., Chow C.K., Steinberg S.M., Nguyen D., et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 14 (2008) 2710-2716
21. Rockberg J., Lofblom J., Hjelm B., Uhlen M., and Stahl S. Epitope mapping of antibodies using bacterial surface display. Nat. Methods 5 (2008) 1039-1045
22. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363-365
23. Schechter A.L., Hung M.C., Vaidyanathan L., Weinberg R.A., Yang-Feng T.L., Francke U., Ullrich A., and Coussens L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229 (1985) 976-978
24. Schwenk J.M., Lindberg J., Sundberg M., Uhlen M., and Nilsson P. Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics. Mol. Cell. Proteomics 6 (2007) 125-132
25. Sharon J., Liebman M.A., and Williams B.R. Recombinant polyclonal antibodies for cancer therapy. J. Cell Biochem 96 (2005) 305-313
26. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
27. Spiridon C.I., Ghetie M.A., Uhr J., Marches R., Li J.L., Shen G.L., and Vitetta E.S. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8 (2002) 1720-1730
28. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137